Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4 publications
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 27, 2014
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Journal: Blood
Published: September 24, 2013
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 25, 2013
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
Journal: Blood
Published: December 14, 2011
Showing 1-4 of 4
Last Updated: 09/26/2026